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Introduction 1 Celecoxib is a non-steroidal anti-inflammatory drug used by millions of patients to 2 alleviate the pain and inflammation associated with diseases such as rheumatoid arthritis (Bessone 3 et al., 2016). Reviews of controlled trials have found no significant difference in the incidence of 4 liver damage between patients administered celecoxib and those receiving placebo (Bessone et al., In this study, we treated mice with CCl4 over a five-week period to induce liver fibrosis.
21
Interestingly, we found that markers of fibrosis were elevated in the mice that received both 22 celecoxib and CCl4 compared to those animals receiving CCl4 alone. Modulation of the EETs by 23 This article has not been copyedited and formatted. The final version may differ from this version. 
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6 either an sEH inhibitor or a dual inhibitor of COX-2 and sEH, blunted some aspects of the pro-1 fibrotic effect of COX-2 inhibition in the CCl4 background. The mice were randomly divided into five experimental groups (6 animals/group): (1) Control,
18
(2) CCl4 only, (3) Celecoxib+CCl4, (4) Celecoxib+TPPU+CCl4, (5) PTUPB+CCl4. CCl4 was 19 administered following a protocol described in detail in (Constandinou et al., 2005) . Briefly, CCl4 Hydroxyproline content was determined following a method in (Reddy and Enwemeka, 1996).
12
Briefly, 10 µL of 10 N NaOH was added to 40 µL of 0.33 mg/µL liver tissue homogenate and the 13 solution was autoclaved at 120 °C for 25 min. After the reaction cooled to room temperature, 14 chloramine T reagent (0.84% chloramine-T, 42 mM sodium acetate, 2.6 mM citric acid, and 39.5% 15 isopropanol) was added (450 µL) bringing the volume to 500 µL. After incubation at room 16 temperature for 25 min, DMAB reagent, 15% 4-(dimethylamino)benzaldehyde in 2:1 (v/v) 17 isopropanol/perchloric acid mixture, was added (500 µL) bringing the volume to 1 mL. The 
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Liver tissue was immediately stored in RNA later solution (Thermo Fisher Scientific, Waltham, 1 MA USA) for 24 h at 4 °C before freezing at -80 °C. Tissue was homogenized using a roto stator 2 grinder (IKA Works Inc., Wilmington, NC, USA) and passed through a QIAshredder column 3 (Qiagen, Valencia, CA, USA). Total RNA was purified using RNeasy kit (Qiagen). cDNA 4 synthesis from total RNA was performed by the QuantiTect Reverse Transcription Kit (Qiagen). Data Table S1 . PTUPB+CCl4. The drugs were loaded into minipumps so that the calculated dose of each 6 compound would be 10 mg/kg/day.
7
When we examined plasma levels of the drugs, we found that the TPPU and celecoxib Celecoxib increased collagen deposition and liver damage in CCl4 treated mice 18 Trichrome staining revealed that the Celecoxib+CCl4 had a higher amount of collagen 19 deposition than the CCl4 only group (Figure 1 Table S1 . Figure 2B ). In the case of MMP-9, levels in the Celecoxib+CCl4, 1 Celecoxib+TPPU+CCl4 and PTUPB+CCl4 groups, while not different than CCl4 only group, were 2 also not different than the Control group (p-value > 0.05) ( Figure 2C ). TIMP-1 was elevated in the 3 CCl4 only group, but the further increase observed in the Celecoxib+CCl4, Celecoxib+TPPU+CCl4 4 and PTUPB+CCl4 groups did not reach significance ( Figure 2D ). For TGF-β, the levels of the 5 Celecoxib+CCl4 and Celecoxib+TPPU+CCl4 groups were lower than the CCl4 only group, but this 6 difference did not reach statistical significance (Figure 2E) . Figure 3F ), these groups were also not different than the Control group.
13
To assess hepatic stellate cell (HSC) activation, we performed IHC on liver tissue with an 14 anti-αSMA (smooth muscle actin) antibody (Figure 4 ). We found that HSC activation was greatest 15 in the Celecoxib+CCl4 group, where it was significantly increased relative to both the Control and Although they did not reach the level of statistical significance, PGJ2 and 15-deoxy-Δ 12,14 -PGJ2 10 show similar trends, the Celecoxib+CCl4 group being lower than the CCl4 only group.
11
Interestingly, the LOX metabolite of arachidonic acid, Lipoxin A4 (LXA4) was significantly 12 elevated by celecoxib ( Figure 5E ). The complete oxylipid profile is summarized in Supplemental   13   Data Table S4 . Figure S3 and Table S4 ). Although the differences in the levels of these analytes did not 16 achieve statistical significance between any of the groups, the means for 8,9-, 11,12-, and 14,15- Changes in associated oxylipid mediators will be discussed below. Interestingly, we saw a slight 19 reduction in F4/80 expression, a marker of macrophages, in the Celecoxib+CCl4 group compared 20 to the CCl4 only group, indicating that the increase in fibrosis in the Celecoxib+CCl4 group is not 21 due to increased macrophage migration.
22
The downstream COX-2 metabolites PGE2 and 15-deoxy-Δ 12,14 -PGJ2 have been proposed However, 15-deoxy-Δ 12,14 -PGJ2 has also been shown to induce apoptosis of human 10 myofibroblasts, a process that contributes to the resolution of fibrosis (Li et al., 2001).
11
We performed an analysis of oxylipids of the arachidonic acid cascade to determine the 12 effect of COX-2 and sEH inhibition. Overall, we found that COX metabolites were elevated in the 13 CCl4 only group, though the levels did not reach statistical significance in most cases. PGE2 levels 14 were elevated in the CCl4 only group and substantially lowered in the Celecoxib+CCl4 group as 15 expected for a COX inhibitor. As outlined above, there was extensive fibrosis in both of these 16 groups, the greatest degree of fibrosis found in the Celecoxib+CCl4 group where the lowest PGE2 17 level was detected. Consistent with an anti-inflammatory effect of celecoxib in the liver, LXA4 18 was greatly elevated by celecoxib. Interestingly, treatment with TPPU and celecoxib or the dual 19 COX-2/sEH inhibitor in the CCl4 background raised PGE2 levels and lowed LXA4 levels compared 20 to the Celecoxib+CCl4 group, in both cases bringing the levels of these lipid mediators closer to 21 those observed in the Control group. It is possible that a drastic reduction in inflammatory on the inflammatory state of the liver, an elevation in PGE2 levels will either increase or decrease 1 liver damage and fibrosis. This might explain some of the contradicting conclusions regarding the 2 role of PGE2 in different liver fibrosis models.
3
There was high variation in the PGJ2 and 15-deoxy-Δ 12,14 -PGJ2 levels, but the trend of 4 metabolites was similar. While CCl4 elevated their mean levels compared to the Control group, 5 the levels were slightly decreased in other groups. Based on these data, the 15-deoxy-Δ 12,14 -PGJ2 6 levels do not explain the increased fibrosis in the Celeoxib+CCl4 group, or the attenuation in 7 fibrosis after TPPU co-treatment. Finally, although the differences observed in the EETs did not achieve statistical 8 significance, the trends suggest that the sEH inhibitors were able to elevate hepatic EET levels, 9 although CCl4 treatment also raised the level of these oxylipids. Given the variation in the data one 10 must use caution in interpretation, but it is possible that the slight increase in EET levels after CCl4 11 treatment is insufficient to counteract pro-fibrotic environment and that the further increase in 12 EETs caused by sEH inhibition tips the balance, partially countering the pro-fibrotic effects of 13 celecoxib in the CCl4 background. In the oxylipin, as well as the mRNA expression and 14 histological analyses, small n sizes might be responsible for trends not reaching significance in 15 this study. Given the variability of fibrotic and inflammatory responses in chronic studies, small 16 group sizes can limit the ability to detect differences between groups.
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21 and damage. Figure 1 . Celecoxib increases the collagen deposition caused by CCl4 treatment. Mice were 2 injected (i.p.) with CCl4 for 5 weeks. The inhibitors were administered subcutaneously via osmotic 3 minipumps that delivered the compounds at a calculated dose of 10 mg/kg/day for a 30 gram Table S3 . Table S3 . Table   7 S3. Table S3 . Table S3 . Table 1 . Histological scoring of H&E-stained sections for inflammation, fibrosis and cellular 2 damage on a 0-3 scale as described in Supplemental Data Table S1 . 
